– Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization – – Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively – – Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor